Administrative Core

行政核心

基本信息

项目摘要

Project Summary. The Center for the Study of Tobacco Products (CSTP) aims to build upon previous successful work on tobacco product evaluation by moving to an integrative theme of impact analysis. The rationale for this effort is that it will provide a transdisciplinary model with which empirical data from several domains can help FDA to predict the extent to which potential tobacco product regulation is likely to meet the mandated “public health standard”. The CSTP’s vision is to provide tools that can be used to guide regulation development so that, by the time a regulation goes into effect, validated methods have been used to test it, refine it, and generate data showing that its health-promoting effects are maximized and that any harmful, unintended consequences are minimized. To realize this vision, the CSTP builds on an existing team of scientists and educators from multiple disciplines to conduct hypothesis-driven research and test population- level predictions. A Center with a complex collaborative and transdisciplinary research vision requires a strong administrative structure to support it. Thus, the specific aims of the Administrative Core are to: (1) facilitate financial and managerial processes, (2) establish mechanisms for evaluation of progress (3) foster intra-, inter-, and extra-Center collaboration, (4) disseminate results to FDA, NIH, and other scientists and policymakers (5) provide centralized recruitment, data management, biostatistical, and participant protections support, and (6) respond rapidly to regulatory needs. In sum, the Administrative Core will continue to serve and strengthen the CSTP by reducing management burden; tracking benchmarks of project and Center success; integrating investigators, appointees, and non-center scientists into CSTP activities; ensuring knowledge transfer to the public, scientific, and decision-making communities; providing recruitment support and biostatistical expertise; and responding rapidly to FDA needs. The Administrative Core is led by a team with a proven track record in transdisciplinary collaboration, project management, reporting, communication and dissemination.
项目摘要。烟草产品研究中心(CSTP)旨在建立在以前的 通过转向影响分析的综合主题,成功的烟草产品评估工作。这 这项工作的理由是,它将提供一个跨学科模型 域可以帮助FDA预测潜在的烟草产品调节的程度 要求“公共卫生标准”。 CSTP的愿景是提供可用于指导法规的工具 开发因此,在监管生效时,已使用经过验证的方法测试它, 完善它,并生成数据,表明其促进健康效应是最大化的,并且任何有害的效果 意想不到的后果最小化。为了实现这一愿景,CSTP建立在现有的团队中 来自多个学科的科学家和教育者进行假设驱动的研究并测试人群 - 水平预测。具有复杂合作和跨学科研究愿景的中心需要强大的 支持它的行政结构。这是行政核心的具体目的是:(1)促进 财务和管理过程,(2)建立评估进度的机制(3) (4)将结果传播给FDA,NIH以及其他科学家和政策制定者(5) 提供集中招聘,数据管理,生物统计和参与保护支持,以及(6) 对监管需求做出迅速反应。总而言之,行政核心将继续服务并加强 CSTP通过减少管理管理伯恩;跟踪项目和中心成功的基准;整合 研究人员,任命和非中心科学家参加CSTP活动;确保知识转移到 公共,科学和决策社区;提供招聘支持和生物统计专业知识; 并迅速响应FDA需求。行政核心由一个团队领导,该团队在 跨学科合作,项目管理,报告,沟通和传播。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS EVAN EISSENBERG其他文献

THOMAS EVAN EISSENBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS EVAN EISSENBERG', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10245299
  • 财政年份:
    2013
  • 资助金额:
    $ 75.62万
  • 项目类别:
Center for the Study of Tobacco Products
烟草制品研究中心
  • 批准号:
    8915111
  • 财政年份:
    2013
  • 资助金额:
    $ 75.62万
  • 项目类别:
Cigarillo smoking: smoke toxicant content and user toxicant exposure and effects
吸烟小雪茄:烟雾有毒物质含量和使用者有毒物质暴露和影响
  • 批准号:
    8545743
  • 财政年份:
    2012
  • 资助金额:
    $ 75.62万
  • 项目类别:
Cigarillo smoking: smoke toxicant content and user toxicant exposure and effects
吸烟小雪茄:烟雾有毒物质含量和使用者有毒物质暴露和影响
  • 批准号:
    8303780
  • 财政年份:
    2012
  • 资助金额:
    $ 75.62万
  • 项目类别:
REALTIME waterpipe tobacco smoke toxicant sampling in the natural environment
自然环境中实时水烟烟雾毒物采样
  • 批准号:
    8409806
  • 财政年份:
    2011
  • 资助金额:
    $ 75.62万
  • 项目类别:
REALTIME waterpipe tobacco smoke toxicant sampling in the natural environment
自然环境中实时水烟烟雾毒物采样
  • 批准号:
    8040720
  • 财政年份:
    2011
  • 资助金额:
    $ 75.62万
  • 项目类别:
REALTIME waterpipe tobacco smoke toxicant sampling in the natural environment
自然环境中实时水烟烟雾毒物采样
  • 批准号:
    8582541
  • 财政年份:
    2011
  • 资助金额:
    $ 75.62万
  • 项目类别:
REALTIME waterpipe tobacco smoke toxicant sampling in the natural environment
自然环境中实时水烟烟雾毒物采样
  • 批准号:
    8209049
  • 财政年份:
    2011
  • 资助金额:
    $ 75.62万
  • 项目类别:
Waterpipe tobacco smoking: trends, toxicants, and capacity building in Jordan
水烟吸食:约旦的趋势、有毒物质和能力建设
  • 批准号:
    7916776
  • 财政年份:
    2009
  • 资助金额:
    $ 75.62万
  • 项目类别:
Waterpipe tobacco smoking: trends, toxicants, and capacity building in Jordan
水烟吸食:约旦的趋势、有毒物质和能力建设
  • 批准号:
    7697276
  • 财政年份:
    2009
  • 资助金额:
    $ 75.62万
  • 项目类别:

相似国自然基金

基加利修正案背景下我国建筑部门的协同减排效益及路径研究
  • 批准号:
    72204017
  • 批准年份:
    2022
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
基加利修正案背景下我国建筑部门的协同减排效益及路径研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development, review, and conduct of Children's Oncology Group (COG) Clinical Trials
儿童肿瘤学组 (COG) 临床试验的开发、审查和实施
  • 批准号:
    10567992
  • 财政年份:
    2023
  • 资助金额:
    $ 75.62万
  • 项目类别:
Public Policy & Health for Substance Exposed Infant-Mother Dyads
公共政策
  • 批准号:
    10643277
  • 财政年份:
    2023
  • 资助金额:
    $ 75.62万
  • 项目类别:
PNA5: A Novel Mas Receptor Agonist for Treatment of Cognitive Impairment in Patients at Risk for Vascular Dementia and Alzheimer's Disease Related Dementia: an FDA required Toxicology Study
PNA5:一种新型 Mas 受体激动剂,用于治疗有血管性痴呆和阿尔茨海默氏病相关痴呆风险的患者的认知障碍:FDA 要求的毒理学研究
  • 批准号:
    10705874
  • 财政年份:
    2023
  • 资助金额:
    $ 75.62万
  • 项目类别:
TELE Para DM: Telemedicine Equity for Limited English Proficient Patients with Diabetes Mellitus in the Safety Net
TELE Para DM:安全网中英语水平有限的糖尿病患者的远程医疗公平性
  • 批准号:
    10598472
  • 财政年份:
    2022
  • 资助金额:
    $ 75.62万
  • 项目类别:
Manufacturing of New Batch AV-1959D Drug Product and Placebo for Phase 1 Trial
为 1 期试验生产新批次 AV-1959D 药品和安慰剂
  • 批准号:
    10732215
  • 财政年份:
    2022
  • 资助金额:
    $ 75.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了